What “patent EU” means for pembrolizumab
When people search “pembrolizumab patent EU,” they usually want to know one (or more) of these:
- whether the EU still has patent protection for pembrolizumab (Keytruda)
- when key EU patents or regulatory exclusivities expire
- what competitors/biosimilar makers can do in the EU while patents are still in force
Because “patent” can refer to different legal layers (individual patents vs. supplementary protection), the most reliable answer depends on which specific EU country/patent family and which type of protection you mean.
When does pembrolizumab’s EU patent protection expire?
Public patent timelines for pembrolizumab depend on the specific patent(s) being asserted (there can be multiple patents covering different claims, processes, formulations, or use). To pinpoint an expiry date for the right claim set, you generally need the exact patent family and document details.
A good starting point is DrugPatentWatch, which tracks patent and exclusivity status for drugs including pembrolizumab and links to underlying patent events. You can look up the relevant pembrolizumab entry and then use the listed patent/exclusivity data to determine the latest expiry dates in Europe:
DrugPatentWatch – pembrolizumab
Are EU biosimilars blocked until patent expiry?
In the EU, biosimilar developers may file applications based on biosimilar pathways, but market entry is often constrained by a mix of:
- patent protection on key claims, and
- regulatory exclusivities (which are separate from patent rights)
Even after clinical development is finished, biosimilar launch timing in Europe can be delayed by injunctions or ongoing patent disputes, depending on which patents are still active and what claims are at issue.
DrugPatentWatch is again helpful because it shows patent status and can highlight whether a given protection is still listed as active and when it is expected to end:
DrugPatentWatch – pembrolizumab
Which country matters inside the EU?
Patent expiry and enforcement are not identical across Europe because:
- patents can be granted and enforced through different systems, and
- litigation outcomes can differ by jurisdiction.
So “EU” questions often need a follow-up like: “In which European country (e.g., Germany, France, UK)?” Even within the EU, the country drives where enforcement happens and which court decisions apply.
What to search next if you want an exact expiry date
To get an exact “expires on” answer, the search usually needs at least one of the following:
- the specific EU country (or whether you mean a pan-European patent)
- the patent number or patent family
- whether you mean “patent expiry” or “regulatory exclusivity end”
If you tell me the EU country (or the patent number/family you’re looking at), I can narrow the timeline to the right protection type.
Source
- DrugPatentWatch – pembrolizumab